Search research articles
Contact Us
Filters
Showing results (51-60 of 170) with videos related to
Page
of 17
Sort By:
Journal of Oncology
|
August 21, 2019
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
Umang Swami, Varun Monga, Aaron D Bossler, et al.
Trends in Cancer
|
July 13, 2023
Advances in the treatment of metastatic prostate cancer
Georges Gebrael, Gliceida Galarza Fortuna, Nicolas Sayegh, et al.
Annals of Translational Medicine
|
July 19, 2021
Current status of intralesional agents in treatment of malignant melanoma
Misam Zawit, Umang Swami, Hassan Awada, et al.
Annals of Translational Medicine
|
July 19, 2021
The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, et al.
Cancers
|
December 11, 2019
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
Austin Greco, Danish Safi, Umang Swami, et al.
Urology Case Reports
|
May 22, 2023
Intraperitoneal seeding of a testicular mixed germ cell tumor following spontaneous intraperitoneal mass rupture with associated anti-NMDA paraneoplastic encephalitis
Morgan B Marshall, Kassandra Dindinger-Hill, Umang Swami, et al.
Oncology Research and Treatment
|
March 31, 2020
A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers
Erin M Mobley, Umang Swami, Sarah Mott, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2018
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?
Umang Swami, Petar Lenert, Muhammad Furqan, et al.
Expert Opinion on Pharmacotherapy
|
August 30, 2024
Talazoparib for the treatment of prostate cancer
Arshit Narang, Chadi Hage Chehade, Zeynep Irem Ozay, et al.
Melanoma Research
|
March 5, 2019
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
Umang Swami, Varun Monga, Michele Freesmeier, et al.
Page
of 17
Search research articles
Search
Showing results (51-60 of 170) with videos related to
Sort By:
Page
of 17
Journal of Oncology
|
August 21, 2019
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
Umang Swami, Varun Monga, Aaron D Bossler, et al.
Trends in Cancer
|
July 13, 2023
Advances in the treatment of metastatic prostate cancer
Georges Gebrael, Gliceida Galarza Fortuna, Nicolas Sayegh, et al.
Annals of Translational Medicine
|
July 19, 2021
Current status of intralesional agents in treatment of malignant melanoma
Misam Zawit, Umang Swami, Hassan Awada, et al.
Annals of Translational Medicine
|
July 19, 2021
The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, et al.
Cancers
|
December 11, 2019
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
Austin Greco, Danish Safi, Umang Swami, et al.
Urology Case Reports
|
May 22, 2023
Intraperitoneal seeding of a testicular mixed germ cell tumor following spontaneous intraperitoneal mass rupture with associated anti-NMDA paraneoplastic encephalitis
Morgan B Marshall, Kassandra Dindinger-Hill, Umang Swami, et al.
Oncology Research and Treatment
|
March 31, 2020
A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers
Erin M Mobley, Umang Swami, Sarah Mott, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2018
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?
Umang Swami, Petar Lenert, Muhammad Furqan, et al.
Expert Opinion on Pharmacotherapy
|
August 30, 2024
Talazoparib for the treatment of prostate cancer
Arshit Narang, Chadi Hage Chehade, Zeynep Irem Ozay, et al.
Melanoma Research
|
March 5, 2019
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
Umang Swami, Varun Monga, Michele Freesmeier, et al.
Page
of 17